

Talvey® (talquetamab-tgvs) (Subcutaneous)

-E-

Document Number: IC-0757

Date Reviewed: 04/2026**Date of Origin: 08/01/2024****Dates Approved: 08/2024, 04/2025, 06/02/2026**

I. Length of Authorization

- Initial: Prior authorization validity will be provided initially for 6 months (180 days), following initial inpatient administration of step-up doses.
- Renewal: Prior authorization validity may be renewed every 6 months (180 days) thereafter.

II. Dosing Limits

Max Units (per dose and over time) [HCPCS Unit]:

- 1280 billable units every 28 days

III. Initial Approval Criteria ¹

Prior authorization validity is provided in the following conditions:

- Member is at least 18 years of age; **AND**
- Used as continuation therapy following inpatient administration of all step-up doses; **AND**
 - Member had an absence of unacceptable toxicity while on inpatient administration of step-up doses; **OR**
 - Provider has confirmed that the first three doses are planned for inpatient administration **AND** will only proceed with continued treatment if the member had an absence of unacceptable toxicity to the inpatient administration of step-up doses

Universal Criteria ¹

- Member does not have an active infection, including clinically important localized infections; **AND**
- Member will be administered prophylaxis for infection according to local guidelines; **AND**
- Member does not have active CNS involvement or clinical signs of meningeal involvement of multiple myeloma; **AND**
- Member has not had an allogenic stem cell transplant within the previous six (6) months or an autologous stem cell transplant within the previous twelve (12) weeks; **AND**

- Member weight and signs of oral and skin toxicity will be monitored at baseline and periodically during therapy; **AND**

Multiple Myeloma † ‡ Φ^{1-5,1e-3e}

- Member has relapsed or refractory disease; **AND**
 - Used as a single agent; **AND**
 - Member has received at least four (4) prior lines of therapy, including a proteasome inhibitor (e.g., bortezomib, carfilzomib, ixazomib, etc.), an immunomodulatory agent (e.g., lenalidomide, thalidomide, pomalidomide, etc.), and an anti-CD38 monoclonal antibody (e.g., daratumumab, isatuximab, etc.) †; **OR**
 - Used in combination with teclistamab; **AND**
 - Member has received at least three (3) prior lines of therapy; **OR**
 - Used as bridging option for B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy

Preferred therapies and recommendations are determined by review of clinical evidence. NCCN category of recommendation is taken into account as a component of this review. Regimens deemed equally efficacious (i.e., those having the same NCCN categorization) are considered to be therapeutically equivalent.

Enhanced Oncology Value (EOV) Program – Redacted indications

Uses not listed above have inadequate data to support efficacy and are excluded from prior authorization validity.

Other treatment options including, but are not limited to, the following may be appropriate: radiation therapy, surgery, traditional chemotherapy (e.g., platinum, taxane), compassionate use/expanded access programs, clinical trials, supportive care, integrative and complementary therapies.

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Φ Orphan Drug

IV. Renewal Criteria¹

Prior authorization validity can be renewed based upon the following criteria:

- Member continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**

- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: cytokine release syndrome (CRS), neurologic toxicity (e.g., Immune Effector Cell-Associated Neurotoxicity Syndrome [ICANS]), severe oral toxicity and weight loss, severe infections, severe cytopenias (e.g., neutropenia, thrombocytopenia, etc.), severe skin toxicity, hepatotoxicity, etc.

V. Dosage/Administration ^{1,6}

Indication	Dose			
Multiple Myeloma	The recommended dosage is administered subcutaneously by a healthcare provider on a weekly or biweekly (every 2 weeks) dosing schedule, until disease progression or unacceptable toxicity.			
	Weekly Dosing schedule	Day	Dose ^a	
	Step-up dosing schedule	Day 1	Step-up dose 1	0.01 mg/kg
		Day 4 ^b	Step-up dose 2	0.06 mg/kg
		Day 7 ^b	First treatment dose	0.4 mg/kg
	Weekly dosing schedule	One week after first treatment dose and weekly thereafter ^c	Subsequent treatment doses	0.4 mg/kg once weekly
	^a Based on actual body weight. ^b Dose may be administered between 2 to 4 days after the previous dose and may be given up to 7 days after the previous dose to allow for resolution of adverse reactions. ^c Maintain a minimum of 6 days between weekly doses.			
	Biweekly (every 2 weeks) Dosing schedule	Day	Dose ^a	
	Step-up dosing schedule	Day 1	Step-up dose 1	0.01 mg/kg
		Day 4 ^b	Step-up dose 2	0.06 mg/kg
		Day 7 ^b	Step-up dose 3	0.4 mg/kg
		Day 10 ^c	First treatment dose	0.8 mg/kg
	Biweekly (every 2 weeks) dosing schedule	Two weeks after first treatment dose and every 2 weeks thereafter ^d	Subsequent treatment doses	0.8 mg/kg every 2 weeks

	^a Based on actual body weight. ^b Dose may be administered between 2 to 4 days after the previous dose and may be given up to 7 days after the previous dose to allow for resolution of adverse reactions. ^c Dose may be administered between 2 to 7 days after step-up dose 3. ^d Maintain a minimum of 12 days between biweekly (every 2 weeks) doses.
<i>Note: Administer Talvey subcutaneously according to the step-up dosing schedule noted above to reduce the incidence and severity of cytokine release syndrome (CRS). Due to the risk of CRS and neurologic toxicity, including ICANS, members should be hospitalized for 48 hours after administration of all doses within the Talvey step-up dosing schedule.</i>	

VI. Billing Code/Availability Information

HCPCS Code(s):

- J3055 – Injection, talquetamab-tgvs, 0.25 mg; 1 billable unit = 0.25 mg

NDC(s):

- Talvey 3 mg/1.5 mL solution for injection in a single-dose vial: 57894-0469-xx
- Talvey 40 mg/mL solution for injection in a single-dose vial: 57894-0470-xx

VII. References (STANDARD)

1. Talvey [package insert]. Horsham, PA; Janssen Biotech, Inc.; October 2025. Accessed April 2026.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for talquetamab. National Comprehensive Cancer Network, 2026. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2026.
3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma, Version 5.2026. National Comprehensive Cancer Network, 2026. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed April 2026.
4. BGM Durie, J-L Harousseau, J S Miguel, et al on behalf of the International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. Sep; 20(9):1467-73.

5. Schinke CD, Touzeau C, Minnema MC, et al. Pivotal phase 2 MonumentAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM). *Journal of Clinical Oncology* 2023 41:16_suppl, 8036-8036.
6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Talquetamab-tgvs: Multiple Myeloma, MUM113. National Comprehensive Cancer Network, 2026. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Guidelines, go online to NCCN.org. Accessed April 2026.

VIII. References (ENHANCED)

- 1e. Chari, Ajai, et al. "Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma." *New England Journal of Medicine*, vol. 387, no. 24, 15 Dec. 2022, pp. 2232–2244, <https://doi.org/10.1056/nejmoa2204591>.
- 2e. Lesokhin AM, Tomasson MH, Bertrand Arnulf, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. *Nature Medicine*. Published online August 15, 2023. doi:<https://doi.org/10.1038/s41591-023-02528-9>
- 3e. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. *New England Journal of Medicine*. 2022;387(6). doi:<https://doi.org/10.1056/nejmoa2203478>
- 4e. Jesús San-Miguel, Binod Dhakal, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. Published online June 5, 2023. doi:<https://doi.org/10.1056/nejmoa2303379>
- 5e. Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. *New England Journal of Medicine*. 2023;388(11):1002-1014. doi:<https://doi.org/10.1056/nejmoa2213614>
- 6e. Sireesha Asoori, Popat R, Joaquín Martínez-Lopez, et al. Real-World Evaluation of Teclistamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM). *Blood*. 2023;142(Supplement 1):3347-3347. doi:<https://doi.org/10.1182/blood-2023-190793>
- 7e. ELREXFIO (elranatamab-bcmm) Clinical Studies | Pfizer Medical Information - US. www.pfizermedicalinformation.com. Accessed June 6, 2024. <https://www.pfizermedicalinformation.com/elrexfio/clinical-studies>
- 8e. Cohen YC, Magen H, Gatt M, et al. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. *N Engl J Med*. 2025;392(2):138. Cohen YC, Magen H, Gatt M, et al. Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma. *N Engl J Med*. 2025;392(2):138.

- 9e. Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. *N Engl J Med*. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455.
- 10e. Offidani M, Corvatta L, Maracci L, et al. Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. *Blood Cancer Journal*. 2013;3(11):e162-e162. doi:https://doi.org/10.1038/bcj.2013.58
- 11e. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. *Blood*. 2012;119(20):4608-4613. doi:https://doi.org/10.1182/blood-2011-12-395715
- 12e. Knop S, Straka C, Haen M, Schwedes R, Hebart H, Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. *Haematologica*. 2005;90(9):1287-1288. Accessed April 12, 2024.
- 13e. Michael M, Bruns I, E Bölke, et al. Bendamustine in patients with relapsed or refractory multiple myeloma. *European journal of medical research*. 2010;15(1):13-13. doi:https://doi.org/10.1186/2047-783x-15-1-13
- 14e. Günther A, Massimo Offidani, Engelhardt M, et al. Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network. *Cancer*. 2021;127(18):3413-3421. doi:https://doi.org/10.1002/cncr.33647
- 15e. Lonial S, Lee HC, Badros A, et al. Pivotal DREAMM-2 study: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-CD38 monoclonal antibodies (mAbs). *Journal of Clinical Oncology* 2020 38:15_suppl, 8536-8536. DOI: 10.1200/JCO.2020.38.15_suppl.8536.
- 16e. Dimopoulos MA, Vânia T.M. Hungria, Atanas Radinoff, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. *The Lancet Haematology*. 2023;10(10):e801-e812. doi:https://doi.org/10.1016/s2352-3026(23)00243-0
- 17e. Bumma N, Richter J, Jagannath, et al. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. *J Clin Oncol*. 2024 Aug 1;42(22):2702-2712. doi: 10.1200/JCO.24.01008. Epub 2024 Jun 16.

18e. Dhakal B, Akhtar OS, Fandrei D, et al. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025 Oct 23;146(17):2063-2072. doi: 10.1182/blood.2025029773.

19e. Costa LJ, Bahlis NJ, Perrot A, et al. Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. Published online December 9, 2025. doi:<https://doi.org/10.1056/nejmoa2514663>

20e. Prime Therapeutics Management. Talvey Clinical Literature Review Analysis. Last updated April 2026. Accessed April 2026.

Appendix A – Non-Quantitative Treatment Limitations (NQTL) Factor Checklist

Non-quantitative treatment limitations (NQTLs) refer to the methods, guidelines, standards of evidence, or other conditions that can restrict how long or to what extent benefits are provided under a health plan. These may include things like utilization review or prior authorization. The utilization management NQTL applies comparably, and not more stringently, to mental health/substance use disorder (MH/SUD) Medical Benefit Prescription Drugs and medical/surgical (M/S) Medical Benefit Prescription Drugs. The table below lists the factors that were considered in designing and applying prior authorization to this drug/drug group, and a summary of the conclusions that Prime’s assessment led to for each.

Factor	Conclusion
Indication	Yes: Consider for PA
Safety and efficacy	Yes: Consider for PA
Potential for misuse/abuse	No: PA not a priority
Cost of drug	Yes: Consider for PA

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C90.00	Multiple myeloma not having achieved remission
C90.02	Multiple myeloma in relapse
C90.10	Plasma cell leukemia not having achieved remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having achieved remission
C90.22	Extramedullary plasmacytoma in relapse
C90.30	Solitary plasmacytoma not having achieved remission
C90.32	Solitary plasmacytoma in relapse
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

Medical Necessity Criteria



Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC